Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Migraine

  Free Subscription


31.10.2022

1 BMC Neurol
1 Brain
5 Headache


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Neurol

  1. POZO-ROSICH P, Dodick DW, Ettrup A, Hirman J, et al
    Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.
    BMC Neurol. 2022;22:394.
    PubMed         Abstract available


    Brain

  2. LACKOVIC J, Price TJ, Dussor G
    MNK1/2 contributes to periorbital hypersensitivity and hyperalgesic priming in preclinical migraine models.
    Brain. 2022 Oct 27. pii: 6775257. doi: 10.1093.
    PubMed         Abstract available


    Headache

  3. YONKER ME, McVige J, Zeitlin L, Visser H, et al
    A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.
    Headache. 2022;62:1207-1217.
    PubMed         Abstract available

  4. STERN JI, Chiang CC, Kissoon NR, Robertson CE, et al
    Narrative review of peripheral nerve blocks for the management of headache.
    Headache. 2022;62:1077-1092.
    PubMed         Abstract available

  5. FISCHER-SCHULTE L, May A
    The 15-day threshold in the definition of chronic migraine is reasonable and sufficient-Five reasons for not changing the ICHD-3 definition.
    Headache. 2022;62:1231-1233.
    PubMed        

  6. BELTRAMONE M, Redon S, Fernandes S, Ducros A, et al
    The teaching of headache medicine in France: A questionnaire-based study.
    Headache. 2022;62:1177-1186.
    PubMed         Abstract available

  7. ORR SL, Shapiro RE
    The elephant in the room: How the underfunding of headache research stunts the field.
    Headache. 2022;62:1234-1238.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: